The present study investigated whether endothelin-1 acts via ET or ET receptors to mediate superoxide anion-induced pain and inflammation. Mice were treated with clazosentan (ET receptor antagonist) or BQ-788 (ET receptor antagonist) prior to stimulation with the superoxide anion donor, KO. Intraplantar treatment with 30 nmol of clazosentan or BQ-788 reduced mechanical hyperalgesia (47% and 42%), thermal hyperalgesia (68% and 76%), oedema (50% and 30%); myeloperoxidase activity (64% and 32%), and overt-pain like behaviours, such as paw flinching (42% and 42%) and paw licking (38% and 62%), respectively. Similarly, intraperitoneal treatment with 30 nmol of clazosentan or BQ-788 reduced leukocyte recruitment to the peritoneal cavity (58% and 32%) and abdominal writhing (81% and 77%), respectively. Additionally, intraplantar treatment with clazosentan or BQ-788 decreased spinal (45% and 41%) and peripheral (47% and 47%) superoxide anion production as well as spinal (47% and 47%) and peripheral (33% and 54%) lipid peroxidation, respectively. Intraplantar treatment with clazosentan, but not BQ-788, reduced spinal (71%) and peripheral (51%) interleukin-1 beta as well as spinal (59%) and peripheral (50%) tumor necrosis factor-alpha production. Therefore, the present study unveils the differential mechanisms by which ET-1, acting on ET or ET receptors, regulates superoxide anion-induced inflammation and pain.

Download full-text PDF

Source
http://dx.doi.org/10.1080/1061186X.2016.1245308DOI Listing

Publication Analysis

Top Keywords

clazosentan bq-788
16
superoxide anion-induced
12
intraplantar treatment
12
bq-788 reduced
12
anion-induced inflammation
8
inflammation pain
8
receptor antagonist
8
superoxide anion
8
treatment 30 nmol
8
30 nmol clazosentan
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!